Professor Jimmy So
Head and Senior Consultant, Division of Surgical Oncology,
National University Cancer Institute of Singapore (NCIS),
Singapore
Advances in immunotherapy and biomarker-driven treatment have rapidly reshaped the management of gastric and gastroesophageal junction (GEJ) adenocarcinoma.1 At the 13th APGCS, an international panel of medical oncologists and s
November 4, 2026
